ACY3 rs2514036: What Your Genotype Means for Bisoprolol Response
The rs2514036 variant is a single-nucleotide polymorphism located in the ACY3 gene on chromosome 11. Research has identified this variant as having a potential association with how an individual's systolic blood pressure responds to treatment with bisoprolol, a common beta-blocker.
What each genotype means
Typical bisoprolol response
This genotype represents the most common form of the ACY3 variant. Research suggests that individuals with this genotype may experience standard blood pressure responses to bisoprolol treatment, though individual results can vary based on other genetic and environmental factors. Please discuss your blood pressure management and medication dosing with your clinician or pharmacist.
This is the most common genotype observed in most global populations.
Potential altered drug response
This genotype includes one copy of the variant associated with altered blood pressure response to certain beta-blockers like bisoprolol. Studies have indicated that this variant may influence how effectively these medications lower blood pressure, though evidence remains mixed across different ancestries. Please consult your healthcare provider or pharmacist regarding your specific treatment plan and medication efficacy.
This genotype is relatively rare and is observed at varying frequencies depending on ancestral background.
Possible reduced drug efficacy
This genotype carries two copies of the variant that has been linked in some studies to a reduced blood pressure response when using bisoprolol. Because this association is based on specific research cohorts, it is important to note that clinical outcomes can differ significantly between individuals. Always discuss your medication response and any concerns about blood pressure control with your doctor or pharmacist.
This genotype is rare in most populations, with higher prevalence noted in some specific ancestral groups.
Understanding the rs2514036 Variant
The rs2514036 variant is a specific change in the DNA sequence located at the transcription start site of the ACY3 gene. In genetics, a single-nucleotide polymorphism, or SNP, represents a variation at a single position in the DNA chain. This particular SNP has been the subject of pharmacogenomic research, which investigates how genetic differences influence an individual's response to medications. Because it sits at the transcription start site, researchers have hypothesized that this variant might influence how the ACY3 gene is expressed or regulated, potentially altering the production of the associated protein. While the location is well-defined, it is important to note that genetic associations are complex and often involve multiple factors beyond a single SNP.
The Role of the ACY3 Gene
The ACY3 gene encodes the enzyme aminoacylase 3. This enzyme is involved in the metabolism of N-acetylated amino acids. In the context of cardiovascular health, research has explored the potential link between ACY3 and the biosynthesis of catecholamines, which are hormones that play a significant role in regulating blood pressure and heart rate. By influencing the metabolic pathways related to these hormones, the ACY3 enzyme may indirectly affect how the body responds to beta-blockers like bisoprolol. Bisoprolol works by blocking beta-1 adrenergic receptors to lower heart rate and blood pressure. Understanding the function of ACY3 provides a biological framework for why variations in this gene might correlate with different clinical outcomes when patients are prescribed this specific class of antihypertensive medication.
Evidence and Research Findings
The association between rs2514036 and bisoprolol response has been observed in clinical studies, such as the Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study. In this research, certain genotypes were associated with a more pronounced decrease in systolic blood pressure following bisoprolol treatment. However, the strength of this evidence is considered moderate. While some studies have reported genome-wide significance, these findings have not always been consistently replicated across all diverse populations or different clinical trials. The field of pharmacogenomics often faces challenges with replication due to differences in study design, population ancestry, and the multifactorial nature of blood pressure regulation. Consequently, while the association is scientifically documented, it is not currently used as a definitive clinical tool for prescribing decisions.
Clinical Implications and Next Steps
It is critical to understand that this information is for educational purposes and does not constitute medical advice. Genetic variants like rs2514036 are only one piece of a much larger puzzle that includes diet, lifestyle, other medications, and overall health status. You should never change your medication dosage or stop taking a prescribed drug based on genetic test results without consulting your healthcare provider. If you are curious about how your genetics might influence your response to blood pressure medication, discuss this with your doctor or a clinical pharmacist. They can provide context based on your full medical history and current clinical guidelines. Pharmacogenomic testing is an evolving field, and clinical decisions should always be based on established medical standards rather than isolated genetic markers.
How common is this variant?
The rs2514036 variant is generally considered rare, with frequency distributions varying across different ancestral populations.
Frequently asked questions
Can I use this genetic information to choose my blood pressure medication?
No. Genetic markers like rs2514036 are not currently used as the primary basis for selecting antihypertensive medications. Always follow the treatment plan prescribed by your physician.
Is rs2514036 a diagnostic test for hypertension?
No, this SNP is not a diagnostic tool for hypertension. It is a research-level marker investigated for its potential association with drug response, not for diagnosing the condition itself.
Why do study results for this SNP vary?
Genetic associations can vary due to differences in study populations, sample sizes, and the complex, polygenic nature of blood pressure regulation. Not all findings are replicated across every study.
Where can I find more information about pharmacogenomics?
You can explore resources like PharmGKB or MedlinePlus Genetics for reliable, evidence-based information on how genes affect drug response. Always discuss these topics with a qualified healthcare professional.
Sources & further reading
Educational information only, last refreshed 10/27/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2514036?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29